- (esketamine) approved in the United States as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson
- FDA approves Johnson & Johnson nasal spray for depression as a stand-alone treatment CNBC
- FDA Allows Standalone Use of Antidepressant Nasal Spray Spravato (Esketamine): Shots – Health News NPR
- SPRAVATO® (esketamine) approved in the United States as first and only monotherapy for adults with treatment-resistant depression PR newswire
- Johnson & Johnson’s Spravato Receives FDA Approval for Use as Monotherapy FiercePharma
(esketamine) approved in the United States as the first and only monotherapy for adults with treatment-resistant depression – Johnson & Johnson
